Pfizer and Gliknik inked a deal worth $25 million up front, plus additional milestones that grant Pfizer worldwide rights to the private company’s human intravenous immunoglobulin, GL-2045, which may be applied to autoimmune diseases.
FierceBiotech says the treatment in question’s “big idea is that its version of FC fusion protein “can be used in much smaller quantities to provide the same or better therapeutic effect than IVIG has.”
Fierce also notes that the treatment bypasses human blood, and could put Pfizer “in a position to make an unlimited quantity to replace what is today a $7 billion product.”
